Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report.
We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.
Cossu
Giovanni
G
Department of Neuroscience A.O.B. S. Michele General Hospital Cagliari, Sardinia, Italy. giovannicossu@aob.it
Melis
Maurizio
M
Melis
Giannina
G
Maccioni
Elisabetta
E
Putzu
Valeria
V
Catte
Olga
O
Putzu
Paolo Francesco
PF
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy; D004421:Dystonia / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005702:Galantamine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D013577:Syndrome
D002800:Cholinesterase Inhibitors; D009465:Neuromuscular Agents; D005702:Galantamine; D019274:Botulinum Toxins, Type A